Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION FDA Response and Labeling work in a 505(b)(2) program relying on literature plus a bridging study now turns on to drop a secondary because a pediatric ethicist objecting to the proposed design put phase-3 protocol with endpoint-sensitivity issues in play. RWE evidence-strategy director should say what phase-3 protocol with endpoint-sensitivity issues proves.

DECISION RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. RWE evidence-strategy director can defend Proceed under protocol from phase-3 protocol with endpoint-sensitivity issues after a pediatric ethicist objecting to the proposed design in a Pharma & Life Sciences challenge. 2. RWE evidence-strategy director cannot defend Proceed under protocol from phase-3 protocol with endpoint-sensitivity issues; Pause the pathway is what the extract actually supports after a pediatric ethicist objecting to the proposed design. 3. A pediatric ethicist objecting to the proposed design never reached the population in phase-3 protocol with endpoint-sensitivity issues — reopen intake, do not close to drop a secondary. 4. Two facts in phase-3 protocol with endpoint-sensitivity issues after a pediatric ethicist objecting to the proposed design conflict for RWE evidence-strategy director; hold this FDA Response and Labeling file.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 2. Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a pediatric ethicist objecting to the proposed design. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read phase-3 protocol with endpoint-sensitivity issues against a pediatric ethicist objecting to the proposed design and write the one fact that would move to drop a secondary for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (phase-3 protocol with endpoint-sensitivity issues after a pediatric ethicist objecting to the proposed design). Lead with the Pharma & Life Sciences option phase-3 protocol with endpoint-sensitivity issues can support after a pediatric ethicist objecting to the proposed design, then the two facts that force it, then the Monday action for RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study.